MX355015B - Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal. - Google Patents

Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal.

Info

Publication number
MX355015B
MX355015B MX2014003256A MX2014003256A MX355015B MX 355015 B MX355015 B MX 355015B MX 2014003256 A MX2014003256 A MX 2014003256A MX 2014003256 A MX2014003256 A MX 2014003256A MX 355015 B MX355015 B MX 355015B
Authority
MX
Mexico
Prior art keywords
indolyl
heart failure
neuronal injury
treating heart
hydroxamates
Prior art date
Application number
MX2014003256A
Other languages
English (en)
Other versions
MX2014003256A (es
Inventor
Chen Yi-Jen
Hung Kuo-Sheng
Kao Yu-Hsun
Liou Jing-Ping
Shan Pei-Wen
Original Assignee
Univ Taipei Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Taipei Medical filed Critical Univ Taipei Medical
Publication of MX2014003256A publication Critical patent/MX2014003256A/es
Publication of MX355015B publication Critical patent/MX355015B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El uso novedoso de moléculas pequeñas, particularmente hidroxamatos de indolilo e indolinilo, se da a conocer en este documento. Los hidroxamatos de indolilo e indolinilo son útiles como compuestos de partida para elaborar un medicamento o una composición farmacéutica para tratar a un paciente que adolece de insuficiencia cardiaca o lesión neuronal.
MX2014003256A 2011-09-15 2012-09-15 Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal. MX355015B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161534902P 2011-09-15 2011-09-15
US201161537589P 2011-09-22 2011-09-22
PCT/US2012/055664 WO2013040520A1 (en) 2011-09-15 2012-09-15 Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury

Publications (2)

Publication Number Publication Date
MX2014003256A MX2014003256A (es) 2014-09-15
MX355015B true MX355015B (es) 2018-04-02

Family

ID=47883813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003256A MX355015B (es) 2011-09-15 2012-09-15 Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal.

Country Status (11)

Country Link
US (1) US9296692B2 (es)
EP (1) EP2763673B1 (es)
JP (1) JP6180417B2 (es)
KR (1) KR20140091522A (es)
CN (1) CN104080451B (es)
AU (1) AU2012308243B2 (es)
CA (1) CA2848877A1 (es)
MX (1) MX355015B (es)
RU (1) RU2615767C2 (es)
TW (1) TWI464147B (es)
WO (1) WO2013040520A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2931345A1 (en) * 2013-11-24 2015-05-28 Taipei Medical University Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits
RS65201B1 (sr) * 2015-10-27 2024-03-29 Univ Taipei Medical Derivati indolina za lečenje i/ili prevenciju fibroznih bolesti
CN107141247B (zh) * 2017-06-02 2020-03-20 烟台大学 抗心脏衰竭化合物、其制备方法及应用
RU2673481C1 (ru) * 2017-12-11 2018-11-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Юго-Западный государственный университет" (ЮЗГУ) Способ комплексной терапии при сочетанной ишемии центральной гемодинамической системы, нижних конечностей, сердца и головного мозга
EP4019806A4 (en) 2019-08-22 2023-04-19 Harmonic Drive Systems Inc. ONE SHAFT GEAR DEVICE

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338755A (en) * 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
US5175164A (en) * 1991-06-05 1992-12-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
JP2881688B2 (ja) * 1995-09-27 1999-04-12 小野薬品工業株式会社 スルホンアミド誘導体
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
DE60020786T2 (de) * 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
JP2001233875A (ja) * 1999-10-12 2001-08-28 Takeda Chem Ind Ltd ピリミジン−５−カルボキサミド化合物、その製造法およびその用途
JP2002371059A (ja) * 2000-05-16 2002-12-26 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
AU2002226634B2 (en) * 2001-03-30 2007-01-25 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
JP2007533749A (ja) * 2004-04-20 2007-11-22 アムゲン インコーポレイティッド アリールスルホンアミドおよびそれに関連する使用方法
CA2576765C (en) * 2004-09-03 2013-05-28 Applied Research Systems Ars Holding N.V. Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
WO2006101456A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
WO2006117165A2 (en) * 2005-05-02 2006-11-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Means and methods for the treatment of head injuries and stroke
AU2006280062A1 (en) * 2005-08-10 2007-02-22 Novartis Ag Method of use of deacetylase inhibitors
GB0526257D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007084625A2 (en) * 2006-01-19 2007-07-26 Mount Sinai School Of Medicine Novel compounds and methods for inhibiting p53 activity
AU2007221020B9 (en) * 2006-02-28 2013-04-04 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
EP2073812A4 (en) * 2006-09-29 2012-08-08 Univ Illinois ACTIVISTS OF HISTONE ACETYLTRANSFERASE AND INHIBITORS OF HISTONE DEACETYLASE IN THE TREATMENT OF ALCOHOLISM
CN101583599A (zh) 2006-12-15 2009-11-18 安斯泰来制药有限公司 N-羟基丙烯酰胺化合物
EP2120910A2 (en) * 2006-12-15 2009-11-25 Novartis Ag Heterocycle compounds and methods of use thereof
CA2695613A1 (en) * 2006-12-19 2008-06-26 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
TW201028421A (en) * 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
BRPI1011192A2 (pt) * 2009-05-07 2016-03-15 Gruenenthal Gmbh derivados de carboxamida e ureia aromáticas substituídas como ligantes de receptor de vaniloide, composição farmacêutica, uso e processo para preparação dos referidos derivados
WO2011022393A2 (en) * 2009-08-17 2011-02-24 The Brigham And Women's Hospital, Inc. Phosphatidylcholine transfer protein inhibitors
FR2949278B1 (fr) * 2009-08-18 2012-11-02 Commissariat Energie Atomique Procede de fabrication d'un dispositif d'emission de lumiere a base de diodes electroluminescentes
TWI429628B (zh) * 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物

Also Published As

Publication number Publication date
WO2013040520A1 (en) 2013-03-21
RU2014114860A (ru) 2015-10-20
TWI464147B (zh) 2014-12-11
TW201313679A (zh) 2013-04-01
US20150065552A1 (en) 2015-03-05
EP2763673B1 (en) 2018-08-01
EP2763673A4 (en) 2015-05-06
RU2615767C2 (ru) 2017-04-11
US9296692B2 (en) 2016-03-29
AU2012308243A1 (en) 2014-04-17
JP2014526518A (ja) 2014-10-06
CN104080451B (zh) 2016-08-24
CA2848877A1 (en) 2013-03-21
MX2014003256A (es) 2014-09-15
KR20140091522A (ko) 2014-07-21
JP6180417B2 (ja) 2017-08-16
EP2763673A1 (en) 2014-08-13
AU2012308243A8 (en) 2014-05-22
CN104080451A (zh) 2014-10-01
AU2012308243B2 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
MX343706B (es) Derivados heterocíclicos novedosos.
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201391752A1 (ru) Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
PH12015502365B1 (en) Bace1 inhibitors
EP2699584A4 (en) CYCLIC PEPTIDE FROM NONOMURAEA SP., METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF MICRO-BACTERIA-INFLAMMATED DISEASES THEREWITH
PH12017500913A1 (en) Substituted bridged urea analogs as sirtuin modulators
MX355015B (es) Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal.
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation
WO2013038200A3 (en) Neurodevelopmental disorders
BR112013023703A2 (pt) composição tópicas que compreendem diamino oxidase para o tratamento ou prevenção de doenças associadas a altos níveis de histamina que envolvem um aumento da dor
WO2011161295A3 (es) Uso de compuestos anticalcineurina para el tratamiento de patologías que cursan con neovascularización ocular

Legal Events

Date Code Title Description
FG Grant or registration